Cyclin-Dependent Kinase 4/6 inhibitors are a newer class of cancer medications that can slow cancer growth by blocking proteins needed for cells to divide and are showing potential of being an additional therapeutic option for this cancer subtype. Here, CDK4 is linked to cancer.